Capsule Summary Slidesets

Share

Program Content

Activities

  • ALTA-1: Brigatinib
    ALTA-1L: Phase III Trial of Brigatinib vs Crizotinib in ALK Inhibitor–Naive Patients With ALK-Positive Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 27, 2018

    Expires: September 26, 2019

  • IMpower132: Atezolizumab
    Phase III IMpower132: Addition of Atezolizumab to First-line Carboplatin/Cisplatin + Pemetrexed in Stage IV Nonsquamous NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2018

    Expires: September 27, 2019

  • IMpower133: Atezo in ES-SCLC
    IMpower133: Addition of Atezolizumab to First-line Carboplatin/Etoposide in Extensive-Stage Small-Cell Lung Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2018

    Expires: September 27, 2019

  • PACIFIC: Durvalumab in Stage III NSCLC
    PACIFIC: Improved OS With Durvalumab vs Placebo After CRT in Unresectable Stage III NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2018

    Expires: September 27, 2019

  • Entrectinib in <i>ROS1</i> NSCLC
    Entrectinib in ROS1-Positive NSCLC: Pooled Analysis of 3 Early-Phase Studies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 02, 2018

    Expires: October 01, 2019

  • Poziotinib in <i>EGFR/HER2</i> Exon 20–Mutated NSCLC
    Phase II Study of Poziotinib, an Investigational TKI, in Heavily Pretreated EGFR or HER2 Exon 20–Mutated NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 02, 2018

    Expires: October 01, 2019

  • NELSON: Low-Dose CT Screening
    NELSON: Reduced 10-Yr Lung Cancer Mortality With Low-Dose CT Screening in High-Risk Current and Former Smokers
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 02, 2018

    Expires: October 01, 2019

  • ALTER1202: Anlotinib in SCLC
    Phase II ALTER1202: Randomized Trial of Anlotinib for SCLC in the Third-line Setting and Beyond
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 02, 2018

    Expires: October 01, 2019

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology